The Asia Pacific Musculoskeletal Diseases Market is projected to be growing at a prominent CAGR between 2021 to 2026. The Asia Pacific Musculoskeletal Diseases market is developing at an exceptionally quick pace.
Musculoskeletal diseases are injuries/pain in the human musculoskeletal system, which also includes the joints, muscles, nerves, tendons, ligaments, and structures that support limbs, neck and back. These are caused by sudden exertion, or they can arise from making the same motions repeatedly. With increasing age the risk of musculoskeletal diseases increases. Also, obese people have high risk of musculoskeletal diseases.
The significant drivers are increase in prevalence of musculoskeletal disorders. Factors like unmet medical needs in developing nations and growing need of drugs related to bones will boost this industry.
The Asia Pacific Musculoskeletal Diseases market is segmented on the basis of Type, Type of Molecules and region. Based on Type the market is segmented into Rheumatoid arthritis, osteoarthritis, osteoporosis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others.. Rheumatoid arthritis has high prevalence and therefore has the largest market share. Based on Type of molecules the market is segmented into biologics and small molecules. Biologics is expected to have the largest market share. Biologics have complex structure which does not allow easy identification or characterization which is driving this segment.
Asia Pacific is geographically segmented into China, India, Japan, South Korea, Taiwan, Australia and South East Asia. Asia Pacific has significant growth owing to growing population and changing growing use of biologics for various musculoskeletal diseases.
AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer,Eli Lilly, Adheron, Alder BioPharmaceuticals, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, , Eupraxia Pharmaceuticals, and GlaxoSmithKline are the some of the key players in the Asia Pacific Musculoskeletal Diseases market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Rheumatoid Arthritis
5.1.3 Osteoarthritis
5.1.4 Osteoporosis
5.1.5 Psoriatic Arthritis
5.1.6 Ankylosing Spondylitis
5.1.7 Fibromyalgia
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Type
5.1.10 Market Attractiveness Analysis, By Type
5.1.11 Market Share Analysis, By Type
5.2 Type Of Molecules
5.2.1 Introduction
5.2.2 Biologics
5.2.3 Small Molecules
5.2.4 Y-o-Y Growth Analysis, By Type Of Molecules
5.2.5 Market Attractiveness Analysis, By Type Of Molecules
5.2.6 Market Share Analysis, By Type Of Molecules
5.3 Treatment
5.3.1 Introduction
5.3.2 Biologics
5.3.3 Corticosteroids
5.3.4 Parathyroid Hormone
5.3.5 Protein Therapy
5.3.6 Selective Estrogen Receptor Modulators
5.3.7 Synthetic Bone Graft
5.3.8 Composite Grafts
5.3.9 Demineralized Bone Matrix
5.3.10 BMPS
5.3.11 Y-o-Y Growth Analysis, By Treatment
5.3.12 Market Attractiveness Analysis, By Treatment
5.3.13 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Type Of Molecules
6.1.3.4 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Type Of Molecules
6.1.4.4 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Type Of Molecules
6.1.5.4 By Treatment
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson Private Limited
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Stryker Corporation
8.3 Akron Molecules
8.4 Adheron
8.5 Bone Therapeutics
8.6 Boehringer Ingelheim
8.7 ChemoCentryx
8.8 Daiichi Sankyo
8.9 GlaxoSmithKline
8.10 Eupraxia Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
